EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elucidating Trigonelline's Therapeutic Mechanisms for Traumatic Brain Injury Through Integrated Network Pharmacology and In Vivo Validation

Qian Zhang iD, Yuefan Zhang, Zhibing Song, Zixiang Tang, Guoqiang Wang, Xiang Yang, Jincai Li iD, Tiejun Li

CNS Neuroscience & Therapeutics · 2026-03 · 32 (3)

DOI: 10.1002/cns.70803 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 09.03.2026. Verfasst von Qian Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, Bozhou University, Bozhou, China. Hauptthemen laut MEDLINE: Alkaloids, Brain Injuries, Traumatic, Network Pharmacology, Neuroprotective Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Specialty Construction Project of Pudong Health and Family Planning Commission of Shanghai, University Synergy Innovation Program of Anhui Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Traumatic brain injury (TBI) triggers complex pathological cascades, including inflammation, oxidative stress, apoptosis, and gliosis, particularly during the acute phase after injury. Trigonelline has been reported to exert neuroprotective effects in experimental models; however, its molecular mechanisms in acute TBI remain insufficiently defined.

Objective

This study aimed to elucidate the molecular targets and mechanisms by which trigonelline attenuates acute TBI using an integrated network pharmacology and experimental validation approach.

Methods

A trigonelline–target interaction network was constructed based on network pharmacology, followed by GO/KEGG analyses to predict the biological processes and pathways involved. Molecular docking was conducted to validate the binding affinity of trigonelline with key targets. Animal experiments were carried out to confirm the mechanistic predictions.

Results

Network pharmacology identified GAPDH, IL6, ALB, TNF, and IL1B as major hub genes associated with trigonelline. GO/KEGG analyses suggested that the neuroprotective effects of trigonelline against TBI primarily involved the MAPK and PI3K‐Akt pathways. In vivo assays demonstrated that trigonelline treatment significantly reduced brain water content, inflammation, and oxidative stress levels within 72 h post‐injury, while ameliorating histopathological damage, as confirmed by ELISA, HE, and LFB staining. TUNEL, NeuN, and FJB staining further revealed that trigonelline attenuated TBI‐induced neuronal apoptosis. Western blotting demonstrated that trigonelline suppressed MMP‐9 and AQP4 expression and attenuated the triggering of the MAPK signaling pathway.

Conclusion

By attenuating MAPK signaling and apoptosis, trigonelline mitigates neural damage following TBI. The present findings provide experimental evidence supporting the neuroprotective effects of trigonelline in an acute TBI model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlkaloidsBrain Injuries, TraumaticNetwork PharmacologyNeuroprotective AgentsDisease Models, AnimalMaleAnimalsMiceMice, Inbred BALB CApoptosisMAP Kinase Signaling SystemOxidative Stress

Stichwörter der Autor:innen

MAPK pathwaymolecular dockingnetwork pharmacologytraumatic brain injurytrigonelline

Substanzen

trigonellineAlkaloidsNeuroprotective Agents

Autor:innen und Institutionen

  • School of Traditional Chinese Medicine, Bozhou University, Bozhou, China.
  • Department of Pharmacy, Punan Hospital, Shanghai, China.
  • School of Medicine, Shanghai University, Shanghai, China.
  • School of Biological and Medical Engineering, Donghua University, Shanghai, China.
  • Zhangjiagang TCM Hospital, Affiliated to Nanjing University of Chinese Medicine, Suzhou, China.

ORCID-Profile: Qian Zhang, Jincai Li

Förderung

  • National Natural Science Foundation of China
  • Key Specialty Construction Project of Pudong Health and Family Planning Commission of Shanghai
  • University Synergy Innovation Program of Anhui Province
  • Bozhou Municipal Key Laboratory of Modern Traditional Chinese Medicine Manufacturing

Zitieren

APA

Zhang, Q., Zhang, Y., Song, Z., Tang, Z., Wang, G., Yang, X., Li, J., & Li, T. (2026). Elucidating Trigonelline's Therapeutic Mechanisms for Traumatic Brain Injury Through Integrated Network Pharmacology and In Vivo Validation. CNS Neuroscience & Therapeutics, 32(3). https://doi.org/10.1002/cns.70803

Vancouver

Zhang Q, Zhang Y, Song Z, Tang Z, Wang G, Yang X, et al. Elucidating Trigonelline's Therapeutic Mechanisms for Traumatic Brain Injury Through Integrated Network Pharmacology and In Vivo Validation. CNS Neuroscience & Therapeutics. 2026;32(3). doi:10.1002/cns.70803

BibTeX
@article{Zhang2026,
  author = {Zhang, Qian and Zhang, Yuefan and Song, Zhibing and Tang, Zixiang and Wang, Guoqiang and Yang, Xiang and Li, Jincai and Li, Tiejun},
  title = {Elucidating Trigonelline's Therapeutic Mechanisms for Traumatic Brain Injury Through Integrated Network Pharmacology and In Vivo Validation},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  volume = {32},
  number = {3},
  doi = {10.1002/cns.70803}
}
Kostenlos starten →